TOVX financials

Theriva Biologics (TOVX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.

TOVX income statement, yearly

YearRevenueGross profitOperating incomeNet incomeEPS
2025––-$24.05M-$25.25M-2.08
2024––-$26.35M-$25.65M-19.03
2023––-$21.43M-$18.35M-28.48
2022––-$21.58M-$20.02M-32.75
2021––-$14.27M-$23.19M-47.50
2020––-$10.16M-$12.56M-165.00